Circulating Lipid Hydroperoxides Predict Cardiovascular Events in Patients With Stable Coronary Artery Disease. The PREVENT Study

Journal of the American College of Cardiology

Volumn 51, Issue 12, 2008, Pages 1196-1202

  Walter, Mary F ^a   Jacob, Robert F ^a,c   Bjork, Rebekah E ^a   Jeffers, Barrett ^b   Buch, Jan ^b   Mizuno, Yoshiko ^a,c   Mason, R Preston ^a,c  

^a ELUCIDA RESEARCH LLC   (United States)

^b PFIZER INC   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; BIOLOGICAL MARKER; INTERCELLULAR ADHESION MOLECULE 1; LIPID HYDROPEROXIDE; PLACEBO; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ADULT; AGED; ANGIOGRAPHY; ARTICLE; CARDIOVASCULAR DISEASE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; CORRELATION ANALYSIS; FEMALE; HAZARD RATIO; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PREDICTION AND FORECASTING; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN BLOOD LEVEL; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; CORONARY ARTERY DISEASE; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYDROGEN PEROXIDE; LIPID PEROXIDATION; LIPID PEROXIDES; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RISK FACTORS;

EID: 40749088885     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2007.11.051     Document Type: Article

References (42)

1. Witztum J.L., and Berliner J.A. Oxidized phospholipids and isoprostanes in atherosclerosis. Curr Opin Lipidol 9 (1998) 441-448
2. Chisolm G.M., and Steinberg D. The oxidative modification hypothesis of atherogenesis: an overview. Free Radic Biol Med 28 (2000) 1815-1826
3. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem 272 (1997) 20963-20966
4. Buffon A., Santini S.A., Ramazzotti V., et al. Large, sustained cardiac lipid peroxidation and reduced antioxidant capacity in the coronary circulation after brief episodes of myocardial ischemia. J Am Coll Cardiol 35 (2000) 633-639
5. Singh R.B., Ghosh S., Niaz M.A., et al. Dietary intake, plasma levels of antioxidant vitamins, and oxidative stress in relation to coronary artery disease in elderly subjects. Am J Cardiol 15 (1995) 1233-1238
6. Sanderson K.J., van Rij A.M., Wade C.R., and Sutherland W.H. Lipid peroxidation of circulating low density lipoproteins with age, smoking and in peripheral vascular disease. Atherosclerosis 118 (1995) 45-51
7. Mosca L., Rubenfire M., Tarshis T., Tsai A., and Pearson T. Clinical predictors of oxidized low-density lipoprotein in patients with coronary artery disease. Am J Cardiol 80 (1997) 825-830
8. Santini S.A., Marra G., Giardina B., et al. Defective plasma antioxidant defenses and enhanced susceptibility to lipid peroxidation in uncomplicated IDDM. Diabetes 46 (1997) 1853-1858
9. Marra G., Cotroneo P., Pitocco D., et al. Early increase of oxidative stress and reduced antioxidant defenses in patients with uncomplicated type 1 diabetes: a case for gender difference. Diabetes Care 25 (2002) 370-375
10. Walter M.F., Jacob R.F., Jeffers B., et al. Serum levels of TBARS predict cardiovascular events in patients with stable coronary artery disease: a longitudinal analysis of the PREVENT study. J Am Coll Cardiol 44 (2004) 1996-2002
11. Pitt B., Byington R.P., Furberg C.D., et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 102 (2000) 1503-1510
12. Mason R.P., Marche P., and Hintze T.H. Novel vascular biology of third-generation L-type calcium channel antagonists: ancillary actions of amlodipine. Arterioscler Thromb Vasc Biol 23 (2003) 2155-2163
13. Mason R.P., Walter M.F., Trumbore M.W., Olmstead Jr. E.G., and Mason P.E. Membrane antioxidant effects of the charged dihydropyridine calcium antagonist amlodipine. J Mol Cell Cardiol 31 (1999) 275-281
14. Chen L., Haught W.H., Yang B., Saldeen T.G.P., Parathasarathy S., and Mehta J.L. Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E, lovastatin and amlodipine. J Am Coll Cardiol 30 (1997) 569-575
15. Franzoni F., Santoro G., Regoli F., et al. An in vitro study of the peroxyl and hydroxyl radical scavenging capacity of the calcium antagonist amlodipine. Biomed Pharmacother 58 (2004) 423-426
16. Nourooz-Zadeh J., Tajaddini-Sarmadi J., and Wolff S.P. Measurement of plasma hydroperoxide concentrations by the ferrous-oxidation xylenol orange (FOX) assay in conjunction with triphenylphosphine. Anal Biochem 220 (1994) 403-409
17. Gay C., Collins J., and Gebicki J.M. Hydroperoxide assay with the ferric-xylenol orange complex. Anal Biochem 273 (1999) 149-155
18. Mancini G.B., Simon S.B., McGillem M.J., LeFree M.T., Friedman H.Z., and Vogel R.A. Automated quantitative coronary arteriography: morphologic and physiologic validation in vivo of a rapid digital angiographic method. Circulation 75 (1987) 452-460
19. National Heart, Lung, and Blood Institute Coronary Artery Surgery study. A multicenter comparison of the effects of randomized medical and surgical treatment of mildly symptomatic patients with coronary artery disease and a registry of consecutive patients undergoing coronary angiography. Circulation 63 Suppl I (1981) I1-I81
20. Byington R.P., Miller M.E., Herrington D., et al. Rationale, design, and baseline characteristics of the Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT). Am J Cardiol 80 (1997) 1087-1090
21. Carbonneau M.A., Peuchant E., Sess D., Canioni P., and Clerc M. Free and bound malondialdehyde measured as thiobarbituric acid adduct by HPLC. Clin Chem 37 (1991) 1423-1429
22. Templar J., Kon S.P., Milligan T.P., Newman D.J., and Raftery M.J. Increased plasma malondialdehyde levels in glomerular disease as determined by a fully validated HPLC method. Nephrol Dial Transplant 14 (1999) 946-951
23. Li X.Y., and Chow C.K. An improved method for the measurement of malondialdehyde in biological samples. Lipids 29 (1994) 73-75
24. Meagher E.A., and Fitzgerald G.A. Indices of lipid peroxidation in vivo: strengths and limitations. Free Radic Biol Med 28 (2000) 1745-1750
25. Rubanyi G.M., and Vanhoutte P.M. Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor. Am J Physiol 250 (1986) H822-H827
26. Kummerow F.A., Olinescu R.M., Fleischer L., Handler B., and Shinkareva S.V. The relationship of oxidized lipids to coronary artery stenosis. Atherosclerosis 149 (2000) 181-190
27. Hazen S.L., Gaut J.P., Crowley J.R., Hsu F.F., and Heinecke J.W. Elevated levels of protein-bound p-hydroxyphenylacetaldehyde, an amino-acid-derived aldehyde generated by myeloperoxidase, are present in human fatty streaks, intermediate lesions and advanced atherosclerotic lesions. Biochemistry 352 (2000) 693-699
28. Hulthe J., and Fagerberg B. Circulating oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines (ARI study). Arterioscler Thromb Vasc Biol 22 (2002) 1162-1167
29. Pratico D. F2-isoprostanes: sensitive and specific non-invasive indices of lipid peroxidation in vivo. Atherosclerosis 147 (1999) 1-10
30. Shishehbor M.H., Brenna M.L., Aviles R.J., et al. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation 108 (2003) 426-431
31. Sabatine M.S., Morrow D.A., O'Donoghue M., et al. Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease. Arterioscler Thromb Vasc Biol 27 (2007) 2463-2469
32. Kiechl S., Willeit J., Mayr M., et al. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-Year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler Thromb Vasc Biol 27 (2007) 1788-1795
33. Sakuma N., Hibino T., Sato T., et al. Levels of thiobarbituric acid-reactive substance in plasma from coronary artery disease patients. Clin Biochem 30 (1997) 505-507
34. Ridker P.M., Hennekens C.H., Roitman-Johnson B., Stampfer M.J., and Allen J. Plasma concentration of soluble intercellular adhesion molecule and risks of future myocardial infarction in apparently healthy men. Lancet 351 (1998) 88-92
35. Haim M., Tanne D., Boyko V., et al. Soluble intercellular adhesion molecule-1 and long-term risk of acute coronary events in patients with chronic coronary heart disease. Data from the Bezafibrate Infarction Prevention (BIP) study. J Am Coll Cardiol 39 (2002) 1133-1138
36. Takei A., Huang Y., and Lopes-Virella M.F. Expression of adhesion molecules by human endothelial cells exposed to oxidized low density lipoprotein. Influences of degree of oxidation and location of oxidized LDL. Atherosclerosis 154 (2001) 79-86
37. Erl W., Weber P.C., and Weber C. Monocytic cell adhesion to endothelial cells stimulated by oxidized low density lipoprotein is mediated by distinct endothelial ligands. Atherosclerosis 136 (1998) 297-303
38. Jialal I., and Devaraj S. Antioxidants and atherosclerosis: don't throw out the baby with the bath water. Circulation 107 (2003) 926-928
39. Steinberg D., and Witztum J.L. Is the oxidative modification hypothesis relevant to human atherosclerosis?. Do the antioxidant trials conducted to date refute the hypothesis?. Circulation 105 (2002) 2107-2111
40. Heinecke J.W. Oxidative stress: New approaches to diagnosis and prognosis in atherosclerosis. Am J Cardiol 91 (2003) 12A-16A
41. Micheletta F., Natoli S., Misuraca M., Sbarigia E., Diczfalusy U., and Iuliano L. Vitamin E supplementation in patients with carotid atherosclerosis: Reversal of altered oxidative stress in plasma but not in plaque. Arterioscler Thromb Vasc Biol 24 (2004) 136-140
42. Mason R.P., Walter M.F., Day C.A., and Jacob R.F. Active metabolite of atorvastatin inhibits membrane cholesterol domain formation by an antioxidant mechanism. J Biol Chem 281 (2006) 9337-9345